Select a medication above to begin.
Ebglyss (lebrikizumab-lbkz)
lebrikizumab
Adult Dosing .
Dosage forms: INJ (pen): 250 mg per injection; INJ (pre-filled syringe): 250 mg per 2 mL
Special Note
- [drug name clarification]
- Info: nonproprietary name = lebrikizumab-lbkz
atopic dermatitis, moderate-severe
- [>40 kg]
- Dose: 250 mg SC q4wk; Start: 500 mg SC x1 on wk 0, 2, then 250 mg SC q2wk until wk 16 or later, then 250 mg SC q4wk
renal dosing
- [see below]
- mild-moderate impairment: no adjustment; severe impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
- Dosage forms: INJ (pen): 250 mg per injection; INJ (pre-filled syringe): 250 mg per 2 mL
Special Note
- [drug name clarification]
- Info: nonproprietary name = lebrikizumab-lbkz
atopic dermatitis, moderate-severe
- [12 yo and older, >40 kg]
- Dose: 250 mg SC q4wk; Start: 500 mg SC x1 on wk 0, 2, then 250 mg SC q2wk until wk 16 or later, then 250 mg SC q4wk
renal dosing
- [see below]
- mild-moderate impairment: no adjustment; severe impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- helminth infection
Drug Interactions .
Overview
lebrikizumab
IL-13 antagonist
- immunomodulatory effects
Contraindicated
Avoid/Use Alternative
Monitor/Modify Tx
Caution Advised
Adverse Reactions .
Serious Reactions
- hypersensitivity reaction
- anaphylaxis
- angioedema
Common Reactions
- conjunctivitis
- injection site reaction
- keratitis
- eosinophilia
Safety/Monitoring .
Monitoring Parameters
no routine tests recommended
Pregnancy/Lactation .
Pregnancy
Clinical Summary
weigh risk/benefit during pregnancy; inadequate human data available, though likely to cross placenta based on human data with other monoclonal antibodies; no known risk of teratogenicity or embryo-fetal toxicity based on animal data at up to 18x MRHD
Pregnancy Reporting
report pregnancy to Eli Lilly and Co. at 1-800-545-5979
Lactation
Clinical Summary
weigh risk/benefit while breastfeeding; no human data available to assess risk of infant harm or effects on milk production
Pharmacology .
Metabolism: for lebrikizumab: catabolism; CYP450: unknown
Excretion: for lebrikizumab: unknown; Half-life: 24.5 days
Subclass: Atopic Dermatitis, Systemic Nonsteroidal Agents ; Interleukin-13 (IL-13) Antagonists
Mechanism of Action
for lebrikizumab: binds to interleukin-13 and inhibits interleukin-13 cytokine-induced responses including release of pro-inflammatory cytokines, chemokines, and IgE (monoclonal antibody)
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.